Recommended Vaccinations for CLL Patient
This 48-year-old man with newly diagnosed CLL should receive pneumococcal vaccination (PCV20 preferred, or PCV15 followed by PPSV23), recombinant zoster vaccine (RZV/Shingrix), Haemophilus influenzae type b (Hib) vaccine, and meningococcal vaccines (both conjugate and serogroup B). 1
Pneumococcal Vaccination - Highest Priority
Since this patient is newly diagnosed with CLL and pneumococcal vaccine-naïve, he should receive:
- PCV20 as a single dose (preferred option), OR
- PCV15 followed by PPSV23 at least 8 weeks later 1
The rationale: CLL patients have a 29- to 36-fold increased risk of invasive pneumococcal disease compared to healthy adults 2. The inherent immune dysfunction in CLL—independent of treatment—makes pneumococcal vaccination critical even in treatment-naïve patients 3.
Timing consideration: Administer now while treatment-naïve, as vaccine responses are significantly better before initiating CLL-directed therapy 2, 4. Treatment status is a major determinant of immunogenicity, with treated patients showing markedly lower serologic protection rates (3%) compared to untreated patients (13%) 2.
Recombinant Zoster Vaccine (RZV/Shingrix)
Administer the 2-dose RZV series (doses 2-6 months apart) 1
- RZV is recommended for all adults ≥18 years at increased risk for herpes zoster, which includes CLL patients 1
- This is a non-live recombinant vaccine, safe in immunocompromised patients
- Critical timing: Give before starting any B-cell depleting therapy if possible, as responses are attenuated after such treatments 3
- If B-cell depleting therapy becomes necessary, RZV can be given as early as 1 month after the most recent dose 3
Haemophilus Influenzae Type b (Hib) Vaccine
Administer Hib vaccine now 1
While data on efficacy in adults is limited, studies suggest good immunogenicity in immunocompromised patients 1. Given the patient's immunocompromised status from CLL, this vaccination is recommended.
Meningococcal Vaccines
Administer both meningococcal conjugate vaccine (MenACWY) and meningococcal B vaccine (MenB) 1
CLL patients are considered immunocompromised and warrant broader meningococcal protection beyond what healthy adults receive.
Vaccines Already Appropriately Received
The patient is appropriately up-to-date on:
- Influenza (annual inactivated or recombinant vaccine is correct) 1
- COVID-19 (boosters appropriate for immunocompromised status) 1
- Tetanus-pertussis (Tdap recently received is appropriate) 1
Critical Timing Strategy
Administer all recommended vaccines immediately, before initiating any CLL-directed therapy. The window of opportunity for optimal vaccine response is now, while the patient is treatment-naïve 3, 2. Once B-cell depleting therapies (anti-CD20 antibodies, BTK inhibitors, BCL-2 inhibitors) are started, vaccine responses become severely attenuated 3, 5.
Key Pitfalls to Avoid
- Do not delay vaccination waiting for "optimal timing"—the best time is before treatment initiation
- Avoid live vaccines entirely in CLL patients, even if untreated, due to subtle T-cell dysfunction 3
- Do not assume prior PPSV23 alone is adequate—conjugated vaccines (PCV) provide superior responses in immunocompromised patients 2, 4
- Remember that household contacts should be up-to-date on all vaccines, particularly avoiding live vaccines that could be shed 1
Future Considerations
If the patient requires B-cell depleting therapy in the future, ideally delay non-seasonal vaccines until 6-12 months after completion of such therapy 3. However, seasonal vaccines (influenza, COVID-19 boosters) should continue even during treatment, despite attenuated responses, as some protection is better than none 3.